BPC-157 and TB-500: Different Tools, Same Stack

Different tools, complementary mechanisms

BPC-157 and TB-500 (Thymosin Beta-4) are the two most commonly stacked peptides for tissue repair and recovery. They work through different pathways and are often used together specifically because their mechanisms are complementary rather than redundant.

BPC-157 works primarily through nitric oxide signaling, growth factor upregulation (VEGF, EGF), and direct cytoprotective effects on gastrointestinal, musculoskeletal, and nervous system tissue.

TB-500 works primarily through actin regulation — it binds G-actin and makes it available for cell migration and tissue remodeling. It promotes angiogenesis (new blood vessel formation) and has documented effects on wound healing and inflammatory modulation.

The rationale for stacking them: BPC-157 initiates and protects the repair process; TB-500 supports the structural remodeling and vascularization phase. They are often described as covering different stages of healing, though the mechanistic picture is still being characterized in research.

Key differences

Typical dosing protocols

These are ranges reported in the research community. Your prescribing provider's protocol may differ — follow their instructions.

• BPC-157: 200–500 mcg/day, once or twice daily, SubQ. For acute injury, some protocols use twice-daily at 250 mcg near the injury site for the first 2 weeks, then maintenance.
• TB-500: Loading phase of 4–8 mg/week for the first 4–6 weeks (split into 2–4 injections), then maintenance of 2 mg/week. Some protocols use 2 mg twice weekly during loading.

The asymmetry in dosing schedules (daily BPC-157 vs. weekly TB-500) is one reason multi-compound tracking matters — if you're logging both in a notes app, the cadence difference creates confusion.

Can they be mixed in one vial?

BPC-157 and TB-500 are commonly mixed in the same vial or drawn into the same syringe for co-injection. They are generally considered compatible in solution. When mixing in one vial, each peptide's concentration is calculated independently based on its amount and the shared bac water volume.

Example: 5 mg BPC-157 + 5 mg TB-500 in a blended vial + 2 mL bac water. Total: 10,000 mcg in 2 mL = 5,000 mcg/mL total (2,500 mcg/mL of each). For 250 mcg BPC-157 + 500 mcg TB-500 = 750 mcg total dose: 750 ÷ 5,000 × 100 = 15 units.

Use the reconstitution calculator and set the vial strength to the combined total (10 mg in the above example) when mixing; My Pep Calc will handle the per-compound dose calculation.

Half-life and dosing cadence side by side

BPC-157's 4-hour half-life and TB-500's ~24-hour half-life mean they clear at very different rates. On a once-daily BPC-157 + twice-weekly TB-500 schedule:

• BPC-157 reaches near-complete clearance between daily doses (over 95% cleared in 20 hours).
• TB-500 accumulates during the loading phase — after 4 twice-weekly injections, trough levels are substantially higher than after dose 1.

See both compounds' curves simultaneously in the half-life chart.

FDA and regulatory status

Neither BPC-157 nor TB-500 is FDA-approved as a finished drug product. Both are available from licensed compounding pharmacies in some US states under prescriber order and from research chemical suppliers. Regulatory status is evolving — verify current legal availability with your prescribing provider.